Corvus Pharmaceuticals Inc. (NASDAQ: CRVS) presented final results from its Phase 1/1b trial of soquelitinib in T cell lymphoma patients ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE